Literature DB >> 31645040

A Comparison of International Management Guidelines for Hidradenitis Suppurativa.

Aleksi J Hendricks1, Jennifer L Hsiao2, Michelle A Lowes3, Vivian Y Shi4.   

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that imparts a significant burden on patients and presents a management challenge for healthcare providers. As attention to this debilitating condition has grown over recent years, our understanding of HS pathogenesis and optimal treatment approaches continues to evolve. Nine HS treatment guidelines developed by various expert organizations have been published, encompassing therapeutic modalities ranging from topical agents to systemic therapies to procedural interventions. These guidelines demonstrate significant overlap in treatment recommendations and have all been published within the last 5 years. Therefore, we aim to compare and synthesize the recommendations of international HS treatment guidelines and to encourage inter-organizational communication for the development of consensus or staggered publication of recommendations for HS management.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Acne inversa; Guidelines; Hidradenitis suppurativa; Management; Treatment; Verneuil’s disease

Year:  2019        PMID: 31645040     DOI: 10.1159/000503605

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  8 in total

1.  Impact of a hidradenitis suppurativa patient decision aid on treatment decision making: A randomized controlled trial.

Authors:  Donna McLean; Olivia McBride; Tanja Samardzic; Mia Sisic; Robert P Dellavalle; Jerry Tan
Journal:  JAAD Int       Date:  2020-10-29

Review 2.  Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.

Authors:  Chun-Hsien Huang; I-Hsin Huang; Cheng-Chen Tai; Ching-Chi Chi
Journal:  Biomedicines       Date:  2022-06-02

3.  Hidradenitis Suppurativa International Online Community: Patient Characteristics and a Novel Model of Treatment Effectiveness.

Authors:  Jen Barak-Levitt; Ron Held; Yossi Synett; Noa Kremer; Emmilia Hodak; Shany Sherman
Journal:  Acta Derm Venereol       Date:  2022-04-04       Impact factor: 3.875

4.  Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.

Authors:  Sophie Glatt; Gregor B E Jemec; Seth Forman; Christopher Sayed; George Schmieder; Jamie Weisman; Robert Rolleri; Seth Seegobin; Dominique Baeten; Lucian Ionescu; Christos C Zouboulis; Stevan Shaw
Journal:  JAMA Dermatol       Date:  2021-11-01       Impact factor: 10.282

Review 5.  Skin manifestations in spondyloarthritis.

Authors:  Katharina Meier; Alexandra Schloegl; Denis Poddubnyy; Kamran Ghoreschi
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

6.  Clinico-Epidemiological Characteristics of Hidradenitis Suppurativa: A Retrospective Cohort Study from a Tertiary Care Centre in Northern India.

Authors:  Divya Kamat; Sunil Gaba; Muthu S Kumaran
Journal:  Indian Dermatol Online J       Date:  2021-06-20

7.  A Novel Technique for the Treatment of a Case of Verneuil's Disease of Perineum and Axillary Regions.

Authors:  Etienne El-Helou; Alaa Kansoun; Elissa Abi Fadel; Ali Nassif; Houssam Bashir Mazraani; Georges Robert Neaime; Houssein Amin Kassem Moussa; Georges Bassil; Serge Ibrahim; Georges R Assaf; Houssam Alam
Journal:  Surg J (N Y)       Date:  2021-07-19

8.  Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.

Authors:  Nobukazu Hayashi; Koremasa Hayama; Kenzo Takahashi; Ichiro Kurokawa; Masateru Okazaki; Tomoko Kashiwagi; Eri Iwashita; Tadashi Terui
Journal:  J Dermatol       Date:  2022-01-17       Impact factor: 3.468

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.